Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Other Operating Expenses (2020 - 2023)

Goldenwell Biotech filings provide 3 years of Other Operating Expenses readings, the most recent being -$68634.0 for Q1 2023.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$68634.0 in Q1 2023 year-over-year; TTM through Dec 2023 was -$68634.0, a N/A change, with the full-year FY2021 number at -$253310.0, changed N/A from a year prior.
  • Other Operating Expenses hit -$68634.0 in Q1 2023 for Goldenwell Biotech, up from -$253310.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$292.0 in Q2 2020 to a low of -$253310.0 in Q4 2021.
  • Median Other Operating Expenses over the past 3 years was -$68634.0 (2023), compared with a mean of -$92959.2.
  • The widest YoY moves for Other Operating Expenses: up 16632.19% in 2021, down 16632.19% in 2021.
  • Goldenwell Biotech's Other Operating Expenses stood at -$292.0 in 2020, then tumbled by 86650.0% to -$253310.0 in 2021, then surged by 72.91% to -$68634.0 in 2023.
  • The last three reported values for Other Operating Expenses were -$68634.0 (Q1 2023), -$253310.0 (Q4 2021), and -$48858.0 (Q2 2021) per Business Quant data.